|Day Low/High||38.90 / 39.31|
|52 Wk Low/High||32.69 / 41.77|
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for...
A glimpse of what to expect during Tuesday's pre-market.
Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.
Big volume is hitting AstraZeneca and a breakout trade could trigger soon.
Higher inflation and, in some parts, solid corporate earnings were both factors on Monday.
U.S. stock futures rise Monday following a record closing high for the Dow Jones Industrial Average to end last week.
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for IMFINZI™ (durvalumab), an...
AstraZeneca's Imfinzi gets reprieve after MYSTIC failure
The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.
The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.
Shares lost more than 16% in London trading
The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.
But not all stocks were helping to push the market higher.
Losses at several major index constituents sank markets Thursday.
These stocks were moving big before the market opened.
Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.
Facebook blows everyone away, again.
AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with TAGRISSO ® (osimertinib) compared to current...
AstraZeneca calls MYSTIC results "disappointing".
Global equity rally takes a breather.
Wall Street's first glimpse at the second quarter.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
AstraZeneca shares rose after the group said its CEO would host an earnings call later this month following speculation he was to take up a similar role Teva Pharmaceuticals.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.